NCT07058103View on ClinicalTrials.gov

Tislelizumab , Cyclophosphamide, Mitoxantrone Liposomes, Chidamide, and Prednisone in the Treatment of R/R AITL

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

April 1, 2025

Primary Completion Date

April 1, 2028

Study Completion Date

April 1, 2028

Conditions
Angioimmunoblastic T-Cell Lymphoma RecurrentAngioimmunoblastic T-Cell Lymphoma Refractory
Interventions
DRUG

tislelizumab in combination with cyclophosphamide, mitoxantrone liposomes, chidamide, and prednisone

tislelizumab: 200mg on d1 every 3 weeks; chidamide: 20mg twice a week at least 3 days apart; cyclophosphamide: 750mg/m2 on Day 1 of each cycle, every 4 weeks; mitoxantrone liposomes: 20mg/m2 on Day 1, every 4 weeks; prednisone: 100mg/day on Day 1 to Day 5 of each course, every 4 weeks.

Trial Locations (1)

221000

RECRUITING

The Affiliated Hospital of Xuzhou Medical University, Xuzhou

All Listed Sponsors
lead

The Affiliated Hospital of Xuzhou Medical University

OTHER